Loreal 2012 Annual Report Download - page 70

Download and view the complete annual report

Please find page 70 of the 2012 Loreal annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 96

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96

GALDERMA
EPIDUO™
Since the end of 2011, Epiduo™ has become
the acne treatment most prescribed by dermatologists
worldwide(3). Originally launched in 2008, the
prescription gel is available in 25 countries. In 2012,
it was introduced in Russia, Mexico and India.
RISING TO NEW CHALLENGES
AT GALDERMA
World number one in dermatology(1), GALDERMA made the most of 2012
by redefining its mission statement, striking the right balance
in its growth drivers and continuing its international expansion.
Operating in more than 70 countries in three
segments—prescription drugs, self-medication
products, and aesthetic and corrective solutions—
GALDERMA is actively continuing its expansion
throughout the world. Its priorities include con-
solidating its partnership with dermatologists
and strengthening its privileged relationship with
a wider circle of healthcare professionals, while
expanding in the New Markets. To remain at the
cutting edge of Research and Innovation, the
laboratory is continuing to make long-term in-
vestments in Research & Development, allocat-
ing around 19% of its annual sales, while setting
up new research partnerships. GALDERMA aims to
strengthen its presence with patients and
healthcare professionals by means of a vast
portfolio of innovative medical solutions for
everyone, at every age. The laboratory’s organic
growth strategy is complemented by its external
growth strategy. For example, in December, the
brand announced the acquisition of the Swiss
laboratory Spirig, the dermatology market leader
in Switzerland(2).
(1) Source: IMS D+J1A+J2A (dermatology only), MAT data,
May 2012. (2) Source: IMS Midas in the dermatology market
(D+J1A+J2A classes), Q4 2012 data. (3) Source: IMS Midas, all
countries chosen in the anti-acne topical treatment market, data
November 2011 to November 2012 town market prescriptions,
sales ex-manufacturer estimated in dollars. (4) Like-for-like.
68